Skip to search formSkip to main contentSkip to account menu

ICRF-187

Known as: ICRF 187, ICRF187 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2013
Review
2013
SIGNIFICANCE Anthracyclines (doxorubicin, daunorubicin, or epirubicin) rank among the most effective anticancer drugs, but their… 
Highly Cited
2007
Highly Cited
2007
Doxorubicin is among the most effective and widely used anticancer drugs in the clinic. However, cardiotoxicity is one of the… 
Highly Cited
2003
Highly Cited
2003
Type IIA topoisomerases both manage the topological state of chromosomal DNA and are the targets of a variety of clinical agents… 
Review
2003
Review
2003
Highly Cited
1996
Highly Cited
1996
PURPOSE We conducted an open-label, randomized trial to determine whether ICRF-187 would reduce doxorubicin-induced… 
Highly Cited
1992
Highly Cited
1992
PURPOSE To test potential protection by ICRF-187 against cumulative doxorubicin-dose-related cardiac toxicity, we conducted a… 
Highly Cited
1992
Highly Cited
1992
In this study doxorubicin, epirubicin, and mitoxantrone were compared for their cardiotoxic potential in a chronic mouse model in… 
Highly Cited
1988
Highly Cited
1988
Studies in animals suggest that the bispiperazinedione ICRF-187 can prevent the development of dose-related doxorubicin-induced… 
Highly Cited
1981